The New Drug Application (NDA) for Zynquista (sotagliflozin; Sanofi and Lexicon) has been accepted by the Food and Drug Administration (FDA), with a Prescription Drug User Free Act (PDUFA) action date set for March 22, 2019. 

Zynquista is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor, intended for use with insulin to improve glycemic control in adults with type 1 diabetes. It works by inhibiting the two proteins responsible for glucose regulation: SGLT1 (responsible for glucose absorption in the GI tract) and SGLT2 (responsible for glucose reabsorption by the kidney). 

The NDA was supported by data from the Phase 3 inTandem clinical trial program which assessed the safety and efficacy of Zynquista in ~3000 adults with inadequately controlled type 1 diabetes.

“If approved, our dual SGLT-1 and SGLT-2 inhibitor, Zynquista, would be the first approved oral therapy used in combination with insulin to improve glycemic control and patient outcomes for adults in the United States who are living with type 1 diabetes,” said Pablo Lapuerta, MD, executive vice president and chief medical officer, Lexicon. “The acceptance of the NDA filing moves us closer to providing a meaningful option for people with type 1 diabetes and we look forward to continuing to work closely with the FDA during the review process.”

Continue Reading

Related Articles


For more information visit or

This article originally appeared on MPR